Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Bortezomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 8/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 8/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 8/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 8/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 7/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 7/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 7/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 7/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 7/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 7/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 7/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 7/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 7/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 7/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 7/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 7/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 7/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 7/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bortezomib SCHEMBL8036967 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL29377226 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL466239 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL685473 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL192129 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL30316729 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8035134 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8049740 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL3676 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL17075366 | 0.99 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110799193-B | Copper and nickel catalyzed decarboxylation borylation | 斯克利普斯研究院 | 2023-12-12 | — | — | CN | disclosed |
| US-20230105887-A1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| EP-4008721-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210395301-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3385267-B1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210171574-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| CN-110799193-A | Copper and nickel catalyzed decarboxylation and boriding reactions | 斯克利普斯研究院 | 2020-02-14 | — | — | CN | disclosed |
| US-20190330270-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. | 2019-10-31 | — | — | US | disclosed |
| EP-2627636-B1 | PROCESS FOR MAKING BORTEZOMIB AND THE INTERMEDIATES FOR THE PROCESS | SYNTHON BV (NL) | 2015-09-02 | — | — | EP | disclosed |
| WO-2015116774-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015056180-A1 | INDOLINE DERIVATIVES AS INHIBITORS OF PERK | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015049650-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049649-A1 | COMBINATION | GBGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
| US-8884009-B2 | Process for making bortezomib and intermediates for the process | SYNTHON BV (NL) | 2014-11-11 | — | — | US | disclosed |
| WO-2014097306-A1 | STABLE AND PURE POLYMORPHIC FORM OF BORTEZOMIB | NATCO PHARMA LIMITED (IN) | 2014-06-26 | — | — | WO | disclosed |
| US-20130203988-A1 | PROCESS FOR MAKING BORTEZOMIB AND INTERMEDIATES FOR THE PROCESS | SYNTHON BV (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-1858913-B1 | MIMETIC PEPTIDES AND THE USE THEREOF IN THE FORM OF 20S, 26S AND IMMUNOPROTEASOME INHIBITORS | UNIV DARMSTADT TECH (DE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009004350-A1 | METHODS FOR PREPARING BORTEZOMIB AND INTERMEDIATES USED IN ITS MANUFACTURE | PLIVA HRVATSKA D.O.O. (HR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105887-A1 | NOVEL PHARMACEUTICAL COMPOSITION | DCPS, SRMS, CYP2D6 | PSMB5 485/4885PSMB8 2159/4885PSMB9 791/4885 |
| US-20190330270-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885PSMB8 43/4885PSMB9 54/4885 |
| US-20210395301-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885PSMB8 43/4885PSMB9 54/4885 |
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, LIPA, ACSL3 | PSMB5 1671/4885PSMB8 2427/4885PSMB9 688/4885 |
| US-20130203988-A1 | PROCESS FOR MAKING BORTEZOMIB AND INTERMEDIATES FOR THE PROCESS | PSMC1, PSMC4, C9 | PSMB5 14/4885PSMB8 21/4885PSMB9 26/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | PSMB5 4092/4885PSMB8 4694/4885PSMB9 4502/4885 |
| US-20210171574-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885PSMB8 43/4885PSMB9 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.